Jefferies Believes ACRS Won’t Stop Here

By Jason Carr

Jefferies analyst David Steinberg reiterated a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS) yesterday and set a price target of $36. The company’s shares closed yesterday at $30.65, close to its 52-week high of $33.25.

According to, Steinberg is a 1-star analyst with an average return of -0.8% and a 45.1% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy.

Based on Aclaris Therapeutics Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $10.69 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $4.71 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing novel drugs to address unmet needs in dermataology . It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.